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In the last decade, it became clear that bile salts (BS), in addition to their role in 
intestinal absorption of lipids and fat-soluble vitamins, are major regulators of 
metabolism. They activate signal transduction pathways through binding to 
the specific BS receptors TGR5 and FXR. Indirectly, BS influence metabolism via 
modification of the gut microbiota ecosystem. The relation between BS metabolism 
and gut microbiota composition is very complex, whereas gut microbiota modulates 
BS structure, creating a complex BS pool consisting of a mixture of differentially 
structured species, BS alter gut microbiota, by disturbing bacterial membrane 
integrity. In addition, to the effects on glucose and energy homeostasis, recent 
literature described a role for BS signaling in control of inflammation and regulation 
of the nervous system. In this review, we discuss a selection of recent published 
studies describing the effects of intestinal BS signaling on health and disease.
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INTRODUCTION
Bile salts (BS) are synthesized in the liver from cholesterol by well-characterized 
biosynthetic pathways. A prominent function of BS is to drive bile formation by the 
liver. Upon release by the intestine, BS promote absorption of dietary fats and fat-
soluble vitamins. In the gut, primary BS are deconjugated, dehydrogenated and 
dehydroxylated by gut microbiota, thereby modifying the physiochemical properties 
of the BS pool. Vice versa, BS can also influence the composition of the microbiota 
because of their anti-microbial properties. Next to their physiochemical properties, 
it is now evident that BS also function as signaling molecules, activating the specific 
BS-activated receptors FXR and TGR5, which modulate expression of target genes 
and trigger cellular downstream signaling cascades, respectively. This review focuses 
on recent advances in the understanding of the role of BS as signaling molecules, 
the cross-talk with the gut microbiota and the function of the BS-activated receptors 
FXR and TGR5 in GLP-1 release, inflammation and energy expenditure.
Bile salt-activated receptors
The best-studied BS-activated receptors, and focus of this review, are the nuclear 
receptor Farnesoid X receptor α (NR1H4/FXRα, from now on referred to as FXR) 1-3 and 
the transmembrane receptor TGR5, also known as G-protein coupled BS receptor 
1 (GPBAR1) 4,5. Note that specific BS can also activate other nuclear receptors, 
such as vitamin D receptor (NR1I1/VDR), constitutive androstane receptor (NR1I3/
CAR), human steroid and xenobiotic receptor (NR1I2/SXR) and its rodent homolog 
pregnane X receptor (PXR) 6,7, however this is outside the scope of this review.
The primary newly synthesized, BS are cholate (CA) and chenodeoxycholate 
(CDCA) in humans, while in rodents CDCA is rapidly converted into the more 
hydrophilic α-muricholate (α-MCA) and β-muricholate (β-MCA). In the liver, BS are 
conjugated to either taurine in rodents or glycine in humans, prior to secretion 
into the bile canalicular lumen and storage in the gallbladder 8. After a meal, the 
conjugated BS will be released from the gallbladder and secreted into the duodenum. 
In the distal ileum, about 95% of the BS are re-absorbed and transported back to 
the liver via the portal blood for re-secretion into bile. The non-absorbed BS traffic 
to the distal ileum and colon where the gut microbiota will deconjugate them and 
convert primary BS into secondary BS - deoxycholate (DCA) and lithocholate (LCA) 
in humans and hyocholate (HCA), hyodeoxycholate (HDCA), murideoxycholate 
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(MDCA), and omega-muricholate (ω-MCA) in rodents - and tertiary BS – for example 
ursodeoxycholate (UDCA)- via oxidation of hydroxyl groups and dehydroxylation, 
hence creating a BS pool containing a mixture of differentially structured species. A 
fraction of the secondary BS is absorbed and the remainder is excreted in the feces. 
This loss of BS will be compensated for by de novo synthesis in the liver (reviewed in 9).
BS regulate their own synthesis in part by activating the nuclear receptor FXR with 
different potencies; CDCA>DCA>LCA>CA 2. Activation of hepatic FXR by BS leads to 
decreased expression of the key enzyme in BS synthesis, cholesterol 7α-hydroxylase 
(CYP7A1), in a short heterodimer partner- (NR0B2/SHP) and liver receptor homolog-1 
(NR5A2/LRH1)-dependent manner 10,11. Hepatic activation of FXR results in decreased 
expression of other enzymes involved in BS synthesis (CYP8B1 and CYP27A1) in a 
SHP- and hepatocyte nuclear factor-4α (HNF4A)-dependent manner 12-15. Activation 
of FXR in the distal ileum by BS results in increased expression of fibroblast growth 
factor 19 (FGF19) in humans and Fgf15 in mice. FGF15/19 is secreted into the portal 
circulation and, via FGF receptor (FGFR) 4 and β-Klotho signaling in the liver, leads to 
repression of CYP7A1 expression 16-18.
Furthermore, BS are also able to activate the transmembrane receptor TGR5, 
also known as G-protein coupled BS receptor 1 and membrane-type BS receptor 
(GPBAR1) 5. TGR5 is a member of the class A rhodopsin-like superfamily of G-coupled 
receptors and is predominantly expressed in gallbladder, ileum, colon (L-cells), 
spleen, adipose tissue, brain and immune cells 4,19-21. Primary and secondary BS can 
activate TGR5, with LCA and DCA as the most efficacious activators. Upon activation 
of TGR5, the receptor internalizes and the G-protein α-subunit is released activating 
adenylate cyclase. In turn, adenylate cyclase induces cAMP synthesis and via protein 
kinase (PKA), the cAMP response element-binding protein (CREB) is phosphorylated 
inducing downstream signaling cascades involved in BS and glucose metabolism, 
energy expenditure, immune response and liver function 5,22.
Bile salts and gut microbiota
Gut microbiota is involved in several intestinal biological functions such as 
defense against pathogens, immunity, development of the intestinal microvilli and 
degradation of non-digestible polysaccharides. Moreover, the gut microbiota is able 
to obtain energy from dietary compounds which were not able to be digested by the 
host. BS concentrations in the distal ileum and colon are one of the multiple factors 
that can influence the composition of the gut microbiota. This antimicrobial activity 
of BS was already described in the middle of the last century 23, though recently 
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many efforts have been made to unravel the exact mechanisms by which BS are able 
to modulate the composition and the number of gut microbiota 24-26. The human gut 
microbiota is a complex community, where more than 90% of the species belong to 
Firmicutes and Bacteroidetes. The human gut microbiota is highly variable between 
individuals. However, a conserved set of colonizers is shared among individuals and 
may be required for the correct function of the gut 27,28. In healthy subjects, some 
of the functions associated with the gut microbiota include: supply of nutrients 
and energy, cancer prevention, inhibition of pathogens, gastrointestinal immune 
function, maintenance of gut motility and cardiovascular health (germ-free state 
results in several impairments to the cardiovascular system 29 (for review see 30,31).
Free BS exert strong anti-microbial activities by disturbing bacterial membrane 
integrity. In this respect, the most hydrophobic (i.e. secondary) BS are the most potent 
ones 26. Administration of cholate for 10 days to rats resulted in specific changes 
in the composition of gut microbiota (increased ratio Firmicutes:Bacteroidetes) 
24. Interestingly, the same bacterial profile was found after high fat diet feeding 
32,33. In addition, dietary fat also alters BS composition, which in turn, favors the 
growth of pro-inflammatory gut microbes 34. Several intestinal pathogens are not 
only bile-resistant but highly favored in the presence of bile, possibly because 
this environment suppressed the symbiotic commensal microorganisms, allowing 
pathogens to establish in the intestine 35,36. Consistent with this hypothesis, previous 
studies in humans have shown an association between inflammatory bowel disease 
and sulphate-reducing bacteria, including B. wadsworthia 37,38. Recently, Devkota and 
colleagues 34 demonstrated that the downside effects of high fat-feeding regarding 
the proliferation of pathogenic species are caused by high content in saturated 
fat (milk-derived). High saturated diet increased hepatic BS synthesis leading to 
increased concentration of taurine-conjugated BS, which allowed the increase of 
pathogens such as B. wadsworthia. Interestingly, these effects were not observed 
when mice were fed low fat diet or high fat diet rich in unsaturated fatty acids. The 
number of B. wadsworthia increases in the presence sulphur-containing organic 
compounds, including taurocholate 39. Furthermore, the increase in abundance of 
B. wadsworthia has been associated with a pro-inflammatory immune response and 
increased incidence of colitis in genetically susceptible IL10 knock-out mice, but 
not in wild-type mice. This microbe has been found in only small numbers in the 
gut of healthy subjects, but it is often detected in higher numbers in patients with 
appendicitis and other intestinal infections 40. However, rodents conjugate their BS 
pool mainly with taurine, whereas in humans BS are mainly conjugated to glycine. 
Therefore, the translation of these results to humans remains to be elucidated. These 
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and other novel results might lead to dietary recommendations to specifically target 
gut microbiota.
Conversely, gut microbiota also influences BS. Already in the 1960s, Wostmann 
reported that absence of gut microbiota in rats was associated with impaired BS and 
cholesterol metabolism. Germ-free rats tend to accumulate more cholesterol than 
their conventional counterparts. In the absence of intestinal flora, rats catabolized 
cholesterol in lesser extent to what it is found in conventional rats 41. Furthermore, 
germ-free rats excreted less fecal BS and showed increased intestinal cholesterol 
absorption, which may explain the increased cholesterol concentrations found 
in the livers of these rats. Cholesterol and BS metabolism are tightly regulated as 
impaired cholesterol metabolism has been linked to changes in BS metabolism due 
to dysregulation of FXR signaling 42-44. The absence of gut microbiota, either in germ-
free or antibiotics-treated animals, led to increased plasma BS levels and decreased 
levels of enterobacteria-biotransformed BS, taurodeoxycholate and cholate 43,45. Ileal 
apical sodium-dependent BS transporter (ASBT/SLC10A2) mRNA and protein levels 
were significantly increased in ampicillin-treated mice compared to vehicle-treated 
mice, indicating that enhanced ileal BS absorption may explain the decreased 
fecal and intestinal BS levels 43.These effects were associated with intestinal FXR 
inactivation, since the expression levels of the intestinal FXR target genes Fgf15 and 
Shp were decreased. In addition, hepatic expression of the BS biosynthetic genes, 
Cyp7a1 and Cyp8b1, was increased which was linked with en expansion of the BS 
pool 46. Interestingly, when antibiotics-treated mice received taurodeoxycholate or 
cholate, differences in mRNA levels of FXR and in expression of target genes were 
not observed. Similarly, mRNA levels of genes involved in BS metabolism were not 
changed in germ-free FXR knock-out mice compared to conventional FXR knock-out 
mice. The differences in the expression pattern of these genes have been attributed 
to changes in the composition of the BS pool, since germ-free animals have a more 
hydrophilic BS pool compared to conventional mice 42,44. Sayin and colleagues 
reported that tauro-conjungated β- and α-muricholate actually function as FXR 
antagonists, which could explain the increased BS synthesis in germ-free mice since 
there is less negative feedback control of their own synthesis when hepatic and 
intestinal FXR is blocked 44.
It is now clear that the relation between gut microbiota and BS metabolism is 
complex. A better understanding of this interaction is needed to design strategies 
aiming at improving human health.
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Bile salts and GLP1 release
The pathophysiology of type 2 diabetes comprises progressive impairment of 
pancreatic β-cells, increased hepatic glucose production and decreased insulin 
sensitivity. In the last decades, many studies have focused on determining the 
role of incretin hormones glucagon-like peptide 1 (GLP1) and glucose-dependent 
insulinotropic polypeptide (GIP) in type 2 diabetes, since they have been associated 
with improved glucose homeostasis 47-49. GIP and GLP1 are synthesized by distinct 
cell types in different regions of the intestine 50. Whereas GIP is synthesized and 
released by the K cells in the duodenum and proximal jejunum, GLP1 is produced by 
the L-cells in the distal intestine (ileum and colon) 51. During fasting conditions, the 
circulating levels of GIP and GLP1 are very low but rapidly increase upon ingestion of 
nutrients 52. In the pancreas, both GLP1 and GIP stimulate glucose-dependent insulin 
secretion and β-cell proliferation, they inhibit β-cell apoptosis and they increase 
insulin production 53. For the purpose of this review, we will limit the discussion to 
the effects of GLP1, because its secretion may be modulated by BS.
Two different mechanisms have been proposed to explain the effects of GLP1 on 
glucose homeostasis: (i) the endocrine pathway and (ii) the neuronal pathway. In the 
endocrine pathway, presence of nutrients in the intestinal lumen (such as glucose, 
galactose, amino acids or fat 52), as well as bile acid dependent-TGR5 activation 
promote GLP1 secretion by the L-cells. GLP1 binds to receptors in several organs, 
including the pancreas, where it increases intracellular cAMP levels to stimulate 
glucose-dependent insulin secretion 51. The existence of a neuronal pathway has 
been suggested because GLP1 and its receptors were expressed in neurons. In the 
neuronal pathway, GLP1 (produced either peripherally or in the central neuronal 
system) promotes satiety and decreases food intake 54 (see section “bile salts and 
nervous system”).
Data from mouse experiments have shown that activation of TGR5 signaling 
pathway after BS or synthetic TGR5 agonist treatment is critical for GLP1 release 55. 
Mice overexpressing TGR5 fed a high fat diet showed improved glucose tolerance, 
increased plasma insulin and GLP1 levels compared to wild-type mice fed a high fat 
diet. Similarly, TGR5 knock-out mice fed a high fat diet showed impaired glucose 
tolerance compared to wild-type mice fed the same diet. In addition, mice receiving 
a TGR5 agonist showed an increased postprandial GLP1 secretion and improved 
insulin homeostasis. 
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A link between BS and glucose homeostasis has also been found in humans 56,57. 
An increase in plasma GLP1, parallel to an increase in BS levels, has been reported 
in obese diabetic patients undergoing bariatric surgery 56,57. In addition, an inverse 
correlation between plasma BS levels and 2-hours postprandial glucose levels, 
as well as a positive correlation between BS and GLP1 levels was found in these 
patients 56, indicating that also in humans BS may be key regulators of GLP1 release. 
Interestingly, recent evidence suggest that treatment with BS resins, which bind 
to BS in the intestinal lumen and thereby increase their fecal excretion, results in 
improved glucose homeostasis in type 2 diabetic patients (for review see 58). One 
of the hypotheses to explain these effects involves increased incretin secretion 
49,59,60 due to TGR5 activation, particularly in the colon 61. Similarly, inhibition of 
BS reabsorption in the ileum after pharmacologically blocking of SLC10A2/ASBT 
resulted in decreased HbA1c and glucose levels and increased plasma insulin and 
GLP-1 levels in a rat model of diabetes (Zucker Diabetic Fatty rat) 62. Overall, these 
data suggest that treatments leading to increased BS concentrations in the colon, 
even bound to a resin, results in stimulation of TGR5-mediated-GLP1 secretion by 
L-cells and an improved glycemic control.
Synthetic GLP1 agonists are available (either as monotheraphy or in combination 
with other antidiabetic agents) for the treatment of diabetes. These agents have 
demonstrated their efficacy to improve glucose homeostasis and promote weight 
loss in several clinical trials 63. It should be noted, however, that some reports have 
associated the treatment with GLP1 agonist with acute pancreatitis in patients with 
type 2 diabetes 64. Another way to increase postprandial GLP1 levels is by blocking 
the protease dipeptidyl peptidase 4 (DPP4). DPP4 is found in many tissues and 
cleaves circulating GLP1 and GIP, resulting in a rapid decay in their actions. DPP4 
knock-out mice showed increased GIP and GLP1 plasma levels, as well as increased 
insulin secretion after oral glucose administration 65. Similarly, type 2 diabetic 
patients treated with DPP4 inhibitors as monotherapy or in combination with other 
hypoglycemic agents, showed decreased blood glucose and HbA1c levels, which 
were associated with increased glucose-mediated insulin release and improved 
pancreatic β-cell function 66. Based on the data available to date, a combined 
therapy using bile acid sequestrants and DPP4 inhibitors could be beneficial in type 
2 diabetic patients in need of aggressive treatment.
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Bile salts and energy expenditure
BS have been reported to act as energy expenditure modulators in a TGR5-
dependent- as well as in a FXR-dependent manner. Administration of BS resulted 
in increased energy expenditure in brown adipose tissue (BAT) of mice fed a high 
fat diet. Similarly, treatment of BAT and skeletal myocytes with BS increased type 
2 iodothyronine deiodinase (D2) activity and oxygen consumption 67. These effects 
did not depend on FXR signaling but on the binding of BS to TGR5 68. Similarly, the 
same research group reported a decrease in body weight in mice fed a high fat diet 
supplemented with a TGR5 agonist compared to high fat diet fed mice 55.
In addition, intestinal BS activation results in a FXR-dependent increase in FGF19/
Fgf15 expression, which has been associated with increased energy expenditure 
69. Transgenic mice overexpressing FGF19 showed increased energy expenditure 
and decreased body weight. These authors concluded that these effects resulted 
from an increased BAT mass and increased β-oxidation due to decreased acetyl-
CoA carboxylase 2 (ACACB/ACC2) expression. The decreased ACC2 expression led 
to reduced levels of malonyl-CoA, which are able to inhibit activity of carnitine 
palmitoyltransferase 1, the rate-limiting enzyme for delivery of fatty acids into the 
mitochondrial matrix prior to β-oxidation. In contrast, whole body FXR activation 
resulted in decreased BS pool size and ultimately induced the development of 
obesity and type 2 diabetes by decreasing energy expenditure in mice 70. 
To date, only two human studies addressed the association of BS as energy 
modulators. Similar to what was found in mouse studies, Ockenga and colleagues 
reported a role of BS as modulators of energy metabolism and thyroid hormone 
control. These authors investigated this association in healthy subjects and in 
cirrhotic patients 71. In contrast, no association between BS and energy expenditure 
was found in patients with type 2 diabetes and in healthy controls before and after 
treatment with BS sequestrants 72. More clinical data is warranted to precisely study 
the potential role of BS as energy modulators.
Bile salts and inflammation
In the last decades, several research groups have been investigating the role of FXR 
in inflammation. The first evidence for this association came from the fact that FXR 
knock-out mice showed increased liver inflammation 73. It has been speculated that 
the mechanisms underlying these effects involves a cross-talk between Nuclear 
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factor-κB (NF-κB; major regulator of the inflammatory response) and FXR since FXR 
activation abolished NF-κB expression, and therefore, reduced inflammation 74. In 
addition, interferon-γ was able to repress FXR in isolated macrophages 75. Due to the 
fact that inflammation plays an important role in many age-related diseases such 
as atherosclerosis, NASH and diabetes, FXR activation may result in improvement of 
these processes.
Emerging roles for FXR in the gut include protection against bacterial overgrowth 
and maintenance of intestinal barrier function. Bile diversion often results in bacterial 
proliferation and mucosal injury which can be inhibited by bile acid administration. 
These effects have been attributed to FXR signaling, because activation of FXR by 
BS resulted in overexpression of genes involved in enteroprotection as well protects 
against bacterial proliferation 76. In addition, a number of studies have demonstrated 
that FXR activation in the intestine improves clinical symptoms and histology in 
murine models of colitis in a FXR-dependent manner 77,78. The increased epithelial 
permeability and expression of pro-inflammatory cytokine genes demonstrated 
in the murine model of colitis, are repressed upon FXR activation, probably via 
repression of NF-κB signaling. Remarkably, FXR is also a target of the inflammatory 
response itself. Intestinal inflammation strongly reduced FXR activation 79. The 
molecular mechanism of the cross-talk between FXR and NF-κB signaling has 
not been fully elucidated, although it has been suggested that it includes FXR 
recruitment to the iNOS promoter, which was correlated with sumoylation of FXR 
(for detailed information regarding the molecular mechanism, see review 80). 
Bile salts and nervous system
Patients with cholestatic diseases often show an accumulation of BS in the peripheral 
circulation 81 which is associated with severe pruritus and analgesia. In addition, 
administration of BS in the skin results in itchiness 82 whereas administration of BS 
sequestrants to cholestatic subjects relieves the pruritus 83. Although this association 
is well-known for many years, two different mechanisms have been proposed to 
explain these effects 84,85. Alemi and colleagues attributed the presence of pruritus 
and analgesia resulting from BS accumulation to a BS-induced TGR5 activation on 
the sensory nerves, which resulted in release of the itch and analgesia transmitters 
(gastrin-releasing peptide and leucine-enkephalin, respectively) 84. TGR5 is also 
expressed in different cell types of the nervous system 4,5,86. Mice receiving BS 
topically on the skin, mice receiving a TGR5 agonist and Tgr5-transgenic mice showed 
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a prominent scratching behavior and this effect was attenuated in Tgr5 knockout 
mice. In contrast, Kremer and colleagues argued that BS sequestration ameliorates 
pruritus in only a small group of cholestatic patients, therefore BS cannot be the 
sole activator of pruritus. These authors found compelling evidence for a role of 
lysophosphatidic acid in initiation of itch. Activity of the enzyme that produces 
lysophosphatidic acid in the plasma, autotaxin correlated well with itching in most 
patients with pruritus 85.
The study of Alemi and colleagues 84 indicates that TGR5 stimulation by BS 
may induce adverse effects. In addition, to the peripheral effects of GLP1 release 
induced by TGR5 activation, the incretin may also induce central effects. It has been 
speculated that GLP1 can bind GLP1 receptors on vagal afferents in the lamina 
propia or in enteric nerves in the intestinal wall before entering the circulation. Data 
supporting this hypothesis originates from the fact that GLP1 decreases gastric 
emptying and intestinal motility 86,87. However, the effects of GLP1 on gastrointestinal 
motor functions seem to be the result of both peripheral and central nervous system 
mechanism. Whereas the peripheral pathway has been associated to changes in 
gastric and intestinal motility 54, interactions of GLP1 with its receptor in the brain 
have been linked to changes in appetite and food and water intake. 
Bile salts and bile salt-activated receptors and lipid disorders
The tight regulation between BS and cholesterol metabolism, makes drugs interfering 
in BS metabolism an attractive target to treat several conditions associated with 
lipid disorders. BS sequestrants (BAS) prevent BS reabsorption in the small intestine, 
hence increasing their fecal excretion 88. Consequently, BS synthesis is increased at 
the expense of plasma LDL-cholesterol. Cholestyramine, colestipol and colesevelam-
HCl, commercially available BAS, showed to have beneficial effects on plasma lipid 
profile in patients suffering from hypercholesterolemia, hypertriglyceridemia, type 2 
diabetes mellitus (T2DM) and increased risk for coronary heart disease (reviewed in 
58). Furthermore, pharmacological activation of the BS-activated receptors FXR and/
or TGR5 also resulted in beneficial effects in the treatment of atherosclerosis and 
energy expenditure. Recently, the potent and specific FXR agonist PX20606 showed 
to effectively induce HDL-mediated transhepatic cholesterol efflux in mice and 
monkeys and reduced atherosclerotic plaque size in an atherosclerotic susceptible 
mouse model 89. The synthesis of these new generation synthetic compounds 
opened a new era and creates possibilities for the use of these pharmacological 
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compounds in the clinic to treat hypercholesterolemia, atherosclerosis and other 
lipid disorders. 
CONCLUSION
The intestine has, next to absorbing nutrients, an important role in regulation of 
metabolism. In this respect, BS are emerging as signaling molecules to maintain 
metabolic control. Activation of the BS receptors FXR and TGR5, has been associated 
with adaptations in glucose and energy homeostasis, as well as with modulation of 
inflammatory processes. In addition, BS are able to interact with and to modify the gut 
microbiota, which also contributes to changes in several metabolic processes (Fig.1). 
Yet, several challenges remain to pinpoint the actual physiological consequences of 
FXR and/or TGR5 activation in health and disease.
Figure 1. Summarizing effects of bile salts in the gut
Bile salts have several effects in the gut which contributes to changes in several metabolic processes. The 
main processes and the locations in the gut are summarized.
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